000			01929nam a22002417a 4500
003			OSt
005			20240305193737.0
008			221125b |||||||| |||| 00| 0 eng d
028			_b Phone: +255 28 298 3384
028			_b Fax: +255 28 298 3386
028			_b Email: vc@bugando.ac.tz
028			_bWebsite: www.bugando.ac.tz
040			_bEnglish _cDLC
041			_aEnglish
100			_aAC Liwa _945987
245			_aBioactive plant molecules, sources and mechanism of action in the treatment of cardiovascular disease
260			_aMwanza, Tanzania: _b Catholic University of Health and Allied Sciences [CUHAS – Bugando] & _bScience Direct _c18 November 2016.
490			_vPharmacognosy Fundamentals, Applications and Strategies
520			_aAbstract::: Cardiovascular diseases (CVDs) are a leading cause of global morbidity, mortality, and health care spending. The current goal of the United Nations is a 25% reduction in deaths owing to noncommunicable diseases such as CVDs by 2025. The economic costs of contemporary therapeutic approaches to reduce the major CVD risk factors of hyperlipidemia, atherosclerosis, and hypertension cannot be sustained on a global scale. Novel sources of bioactive molecules for use in low cost therapies will be essential to accomplish this goal. In this chapter, we review the natural products containing bioactivities for which compelling evidence of efficacy in ameliorating hyperlipidemia, atherosclerosis, and hypertension has been obtained in the laboratory or a clinical setting. The pathophysiological basis of hyperlipidemia, atherosclerosis, and hypertension and current synthetic drug therapies are reviewed and the major sources and candidate bioactive molecules as well as their postulated mechanism(s) of action are discussed.
700			_aEN Barton, _945988
856			_uhttps://doi.org/10.1016/B978-0-12-802104-0.00015-9
942			_2ddc _cVM
999			_c19704 _d19704